PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.70%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
27.70%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
-117.18%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-117.27%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-117.27%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.72%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-138.72%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
64.97%
OCF/share CAGR of 64.97% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
64.97%
OCF/share CAGR of 64.97% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
27.61%
Positive 3Y OCF/share CAGR while CRVO is negative. John Neff might see a big short-term edge in operational efficiency.
64.19%
Positive 10Y CAGR while CRVO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
64.19%
Positive 5Y CAGR while CRVO is negative. John Neff might view this as a strong mid-term relative advantage.
-5.53%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.11%
Negative 3Y equity/share growth while CRVO is at 473.71%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.50%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
We cut SG&A while CRVO invests at 101.38%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.